Andrew M. Baschnagel

Andrew Baschnagel practices at University Health Services - Madison (Highland Ave) in Madison, Wisconsin.

Andrew Baschnagel's NPI, 1578793048, was assigned on July 20, 2009. Andrew Baschnagel graduated from State University of New York at Buffalo School of Medicine in 2009. Andrew Baschnagel holds Wisconsin license 62039.

Andrew Baschnagel's primary practice is University Health Services - Madison (Highland Ave), at 600 Highland Ave, Madison, WI 53792. The practice phone is (608) 265-1978.

Andrew Baschnagel's primary practice is University Health Services - Madison (Highland Ave) in Madison, Wisconsin. Andrew Baschnagel is also affiliated with University Hospital. The medical group on file is UW Health. Andrew Baschnagel's employer is on file too: a school & student health.

Dmand AI tracks the electronic health record (EHR) system at each site where Andrew Baschnagel practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Andrew Baschnagel's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Andrew Baschnagel is licensed in Wisconsin.

CMS data shows 2,116 Medicare services from Andrew Baschnagel across 19 procedure codes in 2024, for 318 Medicare patients. Medicare paid $138,746 for them.

CMS counts 318 Medicare patients who saw Andrew Baschnagel in 2024. The largest group is 65 to 74, with 157 patients. 75% of them have cancer, and 71% have high blood pressure. 9% are also on Medicaid. Their average risk score is 2.01, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Andrew Baschnagel's median patient age at 72, with 56% women.

In 2024, Andrew Baschnagel wrote 19 Medicare Part D claims for 15 patients. 100% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $181 in total drug cost. In 2018, CMS named 14 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Andrew Baschnagel for performance year 2024, reported as part of a group. Andrew Baschnagel accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Andrew Baschnagel as offering telehealth.

Dmand AI links 66 papers to Andrew Baschnagel, published from 2012 to 2025. 2023 was the busiest year, with 7. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Radiosurgery. Andrew Baschnagel has published most often in Int J Radiat Oncol Biol Phys. Andrew Baschnagel's most frequent co-authors are Randall J. Kimple, MD, PhD, Paul M. Harari, MD and Michael F. Bassetti.

Dmand AI links Andrew Baschnagel to 7 clinical trials, 4 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Brain Neoplasms. National Cancer Institute (NCI) sponsors the most, 4.

CMS Open Payments shows 6 general payments to Andrew Baschnagel from 3 drug and device companies from 2016 to 2023. Consulting fees make up the largest share, 76% of the total. AstraZeneca Pharmaceuticals LP paid the most, $1,096.

Andrew Baschnagel graduated from State University of New York at Buffalo School of Medicine in 2009.